MedTrace Logo

PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams

NCT04483635 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2021-05-28

No results posted yet for this study

Summary

In this 16-week randomized control study, health care workers will receive a bolus dose followed by a weekly dose of vitamin D or a placebo bolus and weekly dose. This study will test whether high-dose of vitamin D supplementation decreases the incidence of laboratory-confirmed COVID19 infection (primary outcome), reduces illness severity, duration, as well as work absenteeism among health care workers (HCW) in setting at high-risk of contact with COVID-19 cases in high COVID-19 incidence areas.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo

Weekly oral dose of placebo

DIETARY_SUPPLEMENT

Vitamin D

Weekly oral dose of Vitamin D

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Laboratoire RIVA

    collaborator UNKNOWN

  • St. Justine's Hospital

    lead OTHER

Principal Investigators

  • Francine M Ducharme, MD · St. Justine's Hospital

  • Cecile Tremblay, MD · CHUM

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-08
Primary Completion
2021-05-04
Completion
2021-05-25

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04483635 on ClinicalTrials.gov